Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**S-(2-boronoethyl)-L-cysteine hydrochloride (BEC hydrochloride)** is a boronic acid-based arginine analog and a potent, slow-binding, competitive inhibitor of **arginase I and arginase II**. Its mechanism involves binding to the active site of arginase enzymes, thereby preventing arginine hydrolysis. Reported **Ki** values are 0.4–0.6 μM against recombinant rat arginase I and 0.31 μM (pH 7.5) for human arginase II. BEC hydrochloride is used in biochemical research to investigate the role of arginase in nitric oxide production, endothelial function, inflammation, and cell proliferation, particularly in models of smooth muscle relaxation, pulmonary hypertension, and vascular inflammation. It does not act on inducible nitric oxide synthase at relevant concentrations[2][3][5][6][7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on S-(2-boronoethyl)-L-cysteine hydrochloride.